Levodopa is the gold standard
drug for the symptomatic control of
Parkinson's disease (PD). However, long-term treatment with conventional formulations [
levodopa and a
dopa decarboxylase inhibitor (DDCI)], is associated with re-emergence of symptoms because of wearing-off and
dyskinesia. Treatment with
levodopa/DDCI and
entacapone extends the half-life of
levodopa, avoiding deep troughs in
levodopa plasma levels and providing more continuous delivery of
levodopa to the brain. In this open-label, retrospective, observational study we investigated the effects of
levodopa/DDCI and
entacapone therapy in 800 PD patients with motor fluctuations.
Levodopa/DDCI and
entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and
activities of daily living (
ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in
levodopa dose in 20% of patients. Neurologists preferred
levodopa/DDCI and
entacapone compared with increasing
levodopa dosage, dose-fractionation or addition of a
dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving
ADL (41%). This analysis reveals the preference of neurologists for
levodopa/DDCI and
entacapone over conventional
levodopa-modification strategies for the effective treatment of PD motor fluctuations in clinical practice.